| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Monalizumab Basic information |
| Product Name: | Monalizumab | | Synonyms: | Monalizumab;Research Grade Monalizumab(DHD71901);Research Grade Monalizumab;Monalizumab (anti-NKG2A) | | CAS: | 1228763-95-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Monalizumab Structure]() |
| | Monalizumab Chemical Properties |
| storage temp. | Store at -20°C | | form | Liquid | | color | Colorless to light yellow | | Water Solubility | Soluble in water |
| | Monalizumab Usage And Synthesis |
| Uses | Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells. | | Mechanism of action | Monalizumab is a blocking antibody that prevents the inhibition of
CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting
simultaneously on innate and adaptive immunity, monalizumab may
re-establish a broad anti-tumor response. | | in vivo | Monalizumab (50 μg, intratumoral injections, together with 8millions of activated NK cells) effectively inhibits tumor growth in xenografted HLA-E+ tumors in immunodeficient mice[4].
| Animal Model: | immunodeficient mice xenografted with Cal-27 HLA-E high tumor cell[4] | | Dosage: | 50μg, together with 8millions of activated NK cells | | Administration: | intratumoral injections | | Result: | Shows a synergestic antitumor effect.
Enhanced NK-cell killing, and induces lysis of tumor cells. |
|
| | Monalizumab Preparation Products And Raw materials |
|